Is Krystal Biotech Stock a Good Investment?
Krystal Biotech Investment Advice | KRYS |
- Examine Krystal Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Krystal Biotech's leadership team and their track record. Good management can help Krystal Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Krystal Biotech's business and its evolving consumer preferences.
- Compare Krystal Biotech's performance and market position to its competitors. Analyze how Krystal Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Krystal Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Krystal Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Krystal Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Krystal Biotech is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Krystal Biotech Stock
Researching Krystal Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Krystal Biotech was now reported as 30.81. The company had not issued any dividends in recent years.
To determine if Krystal Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Krystal Biotech's research are outlined below:
| Krystal Biotech generated a negative expected return over the last 90 days | |
| Krystal Biotech is unlikely to experience financial distress in the next 2 years | |
| Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer |
Krystal Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Krystal Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Krystal Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Krystal Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Krystal Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-03-12 | 2017-12-31 | -0.23 | -0.26 | -0.03 | 13 | ||
2019-05-06 | 2019-03-31 | -0.33 | -0.29 | 0.04 | 12 | ||
2019-03-12 | 2018-12-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2019-08-05 | 2019-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2021-03-01 | 2020-12-31 | -0.59 | -0.53 | 0.06 | 10 | ||
2020-08-10 | 2020-06-30 | -0.47 | -0.37 | 0.1 | 21 | ||
2021-05-10 | 2021-03-31 | -0.56 | -0.67 | -0.11 | 19 | ||
2024-05-06 | 2024-03-31 | 0.15 | 0.03 | -0.12 | 80 |
Krystal Biotech Target Price Consensus
Krystal target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Krystal Biotech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Krystal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Krystal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Krystal Biotech, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKrystal Biotech Target Price Projection
Krystal Biotech's current and average target prices are 148.39 and 207.78, respectively. The current price of Krystal Biotech is the price at which Krystal Biotech is currently trading. On the other hand, Krystal Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Krystal Biotech Market Quote on 17th of January 2025
Target Price
Analyst Consensus On Krystal Biotech Target Price
Krystal Biotech Analyst Ratings
Krystal Biotech's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Krystal Biotech stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Krystal Biotech's financials, market performance, and future outlook by experienced professionals. Krystal Biotech's historical ratings below, therefore, can serve as a valuable tool for investors.Know Krystal Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Krystal Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Krystal Biotech backward and forwards among themselves. Krystal Biotech's institutional investor refers to the entity that pools money to purchase Krystal Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jennison Associates Llc | 2024-09-30 | 410.1 K | Amvescap Plc. | 2024-09-30 | 365.6 K | Nuveen Asset Management, Llc | 2024-09-30 | 311.9 K | Goldman Sachs Group Inc | 2024-09-30 | 301.4 K | Lord, Abbett & Co Llc | 2024-09-30 | 284.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 275.8 K | Franklin Resources Inc | 2024-09-30 | 243.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 240.2 K | Northern Trust Corp | 2024-09-30 | 238.7 K | Fmr Inc | 2024-09-30 | 4.3 M | Blackrock Inc | 2024-09-30 | 4 M |
Krystal Biotech's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.16 B.Market Cap |
|
Krystal Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Determining Krystal Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Krystal Biotech is a good buy. For example, gross profit margin measures Krystal Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Krystal Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.
Evaluate Krystal Biotech's management efficiency
Krystal Biotech has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0638 %, meaning that it created $0.0638 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2025, despite the fact that Return On Capital Employed is likely to grow to (0.13). At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2025, whereas Other Assets are likely to drop slightly above 354 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 25.81 | 27.10 | |
| Tangible Book Value Per Share | 25.81 | 27.10 | |
| Enterprise Value Over EBITDA | 151.73 | 159.32 | |
| Price Book Value Ratio | 4.98 | 4.73 | |
| Enterprise Value Multiple | 151.73 | 159.32 | |
| Price Fair Value | 4.98 | 4.73 | |
| Enterprise Value | 2.7 B | 2.9 B |
The strategic vision of Krystal Biotech management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 0.82 |
Basic technical analysis of Krystal Stock
As of the 17th of January 2025, Krystal Biotech secures the Mean Deviation of 2.08, standard deviation of 2.75, and Risk Adjusted Performance of (0.08). Krystal Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Krystal Biotech risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Krystal Biotech is priced some-what accurately, providing market reflects its recent price of 148.39 per share. Given that Krystal Biotech has information ratio of (0.10), we recommend you to check Krystal Biotech's last-minute market performance to make sure the company can sustain itself at a future point.Krystal Biotech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Krystal Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Krystal Biotech's Outstanding Corporate Bonds
Krystal Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Krystal Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Krystal bonds can be classified according to their maturity, which is the date when Krystal Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Krystal Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Krystal Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 2.08 | |||
| Coefficient Of Variation | (977.84) | |||
| Standard Deviation | 2.75 | |||
| Variance | 7.54 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 14.97 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 3.05 | |||
| Skewness | (0.24) | |||
| Kurtosis | 0.884 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 2.08 | |||
| Coefficient Of Variation | (977.84) | |||
| Standard Deviation | 2.75 | |||
| Variance | 7.54 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 14.97 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 3.05 | |||
| Skewness | (0.24) | |||
| Kurtosis | 0.884 |
Consider Krystal Biotech's intraday indicators
Krystal Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Krystal Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3960.34 | |||
| Daily Balance Of Power | 1.091463 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 147.51 | |||
| Day Typical Price | 147.8 | |||
| Price Action Indicator | 2.67 | |||
| Period Momentum Indicator | 3.58 |
Krystal Biotech Corporate Filings
8K | 18th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Krystal Stock media impact
Far too much social signal, news, headlines, and media speculation about Krystal Biotech that are available to investors today. That information is available publicly through Krystal media outlets and privately through word of mouth or via Krystal internal channels. However, regardless of the origin, that massive amount of Krystal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Krystal Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Krystal Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Krystal Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Krystal Biotech alpha.
Krystal Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Krystal Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Krystal Biotech Corporate Management
| Christine Wilson | Head Marketing | Profile | |
| David Chien | Senior Development | Profile | |
| Hubert MD | Senior Development | Profile | |
| Gloria Lin | Accounting Mang | Profile | |
| Kathryn Romano | Executive Officer | Profile | |
| Katherine Tuminello | HR Mang | Profile |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.